Xu XM - Search Results

1

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Hu CY, Xu XM, Hong B, Wu ZG, Qian Y, Weng TH, Liu YZ, Tang TM, Wang MH, Yao HP. Hu CY, et al. Among authors: xu xm. Front Oncol. 2019 Dec 5;9:1377. doi: 10.3389/fonc.2019.01377. eCollection 2019. Front Oncol. 2019. PMID: 31867280 Free PMC article.

2

RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.

Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. Xu XM, et al. Oncogene. 2004 Nov 4;23(52):8464-74. doi: 10.1038/sj.onc.1207907. Oncogene. 2004. PMID: 15378025

3

Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells.

Wang D, Shen Q, Xu XM, Chen YQ, Wang MH. Wang D, et al. Among authors: xu xm. Carcinogenesis. 2005 Jan;26(1):27-36. doi: 10.1093/carcin/bgh284. Epub 2004 Sep 24. Carcinogenesis. 2005. PMID: 15447977

4

Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.

Xu XM, Zhou YQ, Wang MH. Xu XM, et al. J Biol Chem. 2005 Jul 1;280(26):25087-94. doi: 10.1074/jbc.M414699200. Epub 2005 May 6. J Biol Chem. 2005. PMID: 15878878 Free article.

5

Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer.

Xu X, Xiao Y, Hong B, Hao B, Qian Y. Xu X, et al. Cancer Biomark. 2019;25(3):251-257. doi: 10.3233/CBM-190067. Cancer Biomark. 2019. PMID: 31282407

6

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.

Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP. Weng TH, et al. Among authors: xu xm. Cancer Res Treat. 2020 Jul;52(3):973-986. doi: 10.4143/crt.2019.726. Epub 2020 Apr 22. Cancer Res Treat. 2020. PMID: 32324988 Free PMC article.

7

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.

Liu YZ, Han DT, Shi DR, Hong B, Qian Y, Wu ZG, Yao SH, Tang TM, Wang MH, Xu XM, Yao HP. Liu YZ, et al. Among authors: xu xm. World J Gastrointest Oncol. 2020 Nov 15;12(11):1216-1236. doi: 10.4251/wjgo.v12.i11.1216. World J Gastrointest Oncol. 2020. PMID: 33250957 Free PMC article.

8

Application of spontaneously closing cannula ileostomy in laparoscopic anterior resection of rectal cancer.

Chen D, Zhao H, Huang Q, Xu X, Cheng X, Ke B, Wang D, Hua H, Xu J, Lin J, Ye F. Chen D, et al. Oncol Lett. 2017 Nov;14(5):5299-5306. doi: 10.3892/ol.2017.6872. Epub 2017 Sep 1. Oncol Lett. 2017. PMID: 29142601 Free PMC article.

9

Multi-stage resection and repair for the treatment of adult giant sacrococcygeal teratoma: A case report and literature review.

Sheng QS, Xu XM, Cheng XB, Wang WB, Chen WB, Lin JJ, Xu JH. Sheng QS, et al. Among authors: xu jh, xu xm. Oncol Lett. 2015 Jul;10(1):425-429. doi: 10.3892/ol.2015.3249. Epub 2015 May 20. Oncol Lett. 2015. PMID: 26171044 Free PMC article.

10

Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.

Cheng X, Xu X, Chen D, Zhao F, Wang W. Cheng X, et al. Biomed Pharmacother. 2019 Feb;110:473-481. doi: 10.1016/j.biopha.2018.11.082. Epub 2018 Dec 6. Biomed Pharmacother. 2019. PMID: 30530050 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,003 results

Search Page

Filters